Abstract Number: 1299 • ACR Convergence 2024
Board-Style Rheumatology Teaching for Medicine Residents: Novel Approach to Curriculum Development
Background/Purpose: During their training, internal medicine (IM) residents often have limited exposure to rheumatology, resulting in decreased confidence levels and inadequate scores on the In-training…Abstract Number: 1666 • ACR Convergence 2024
Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement
Background/Purpose: After knee replacement (KR), most adults fail to meet recommended levels of physical activity. Virtual options to promote physical activity in clinical populations have…Abstract Number: 1696 • ACR Convergence 2024
Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide with Sequential Azathioprine for Active Takayasu’s Arteritis: An Open-Label, Randomized-Controlled Trial
Background/Purpose: The management of Takayasu’s arteritis (TAK) is challenging for lack of large-scale, high-quality clinical trials. Cyclophosphamide (CYC) is a conventional first-line immunosuppressant but is…Abstract Number: 1940 • ACR Convergence 2024
Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative
Background/Purpose: Uveitis is the inflammation of the eye, which is third leading cause of preventable blindness in the United States. Corticosteroids are the first line…Abstract Number: 2527 • ACR Convergence 2024
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues.…Abstract Number: 0298 • ACR Convergence 2024
RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…Abstract Number: 0300 • ACR Convergence 2024
Evaluation of Long-term Primary Patency of Iliocaval Stenting in Patients with Retroperitoneal Fibrosis/chronic Periaortitis
Background/Purpose: Idiopathic retroperitoneal fibrosis (RPF) / chronic periaortitis (CP) is an uncommon condition characterized by a fibroinflammatory periarterial soft tissue thickening around the infra-renal abdominal…Abstract Number: 0338 • ACR Convergence 2024
Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort
Background/Purpose: Anti-melanoma differentiation-associated protein 5 antibody associated dermatomyositis (Anti-MDA5 DM) is known to be an aggressive disease. Earlier cohorts reported a 1-year mortality of 38%-57%, with rapidly…Abstract Number: 0426 • ACR Convergence 2024
Quality Improvement Initiative to Increase Contraception Screening and Documentation for Reproductive-Aged Women Prescribed Teratogenic Medications in an Academic Rheumatology Center
Background/Purpose: Rheumatology patients prescribed teratogenic medications often are not prescribed effective contraception. Efforts to improve this important quality indicator are limited by inadequate and poorly…Abstract Number: 0672 • ACR Convergence 2024
Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Background/Purpose: Many cytokines implicated in lupus pathogenesis depend on JAK signaling to exert their intracellular action. Tofacitinib (TOFA) inhibits signaling by cytokine receptors associated with…Abstract Number: 1053 • ACR Convergence 2024
Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases
Background/Purpose: Medication nonadherence is as high as 75% among patients with rheumatic diseases, leading to increased morbidity, mortality, and cost. Existing adherence interventions tend to…Abstract Number: 1058 • ACR Convergence 2024
Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project
Background/Purpose: When pediatric rheumatology patients are discharged from a hospital, the period between hospital discharge & outpatient care transition creates a care gap when there…Abstract Number: 1063 • ACR Convergence 2024
AI –Driven Precision in Rheumatologic Emergencies: Unveiling the Capability of Top Healthcare Chatbots
Background/Purpose: Rheumatologic emergencies are severe, with mortality rates up to 50% even with timely intervention. Associated morbidity includes permanent organ failure and significant disability. This…Abstract Number: 1065 • ACR Convergence 2024
A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications
Background/Purpose: Many patients with systemic lupus erythematosus (SLE) require teratogenic medications for management of their disease. Reliable contraception is important to avoid unintended pregnancy in…
- 1
- 2
- 3
- …
- 7
- Next Page »